Should it be approved, BioMarin is considering pricing Valrox, a gene therapy drug aimed at hemophilia A, at $2 million to $3 million for the single treatment.
Read moreZolgensma and Gene Therapy: What is the Cost?
Gene therapy in healthcare has become a reality, and it is set to move from a trickle to a stream in the next few years. This article discusses Zolgensma and other emerging gene therapies in the context of how they may affect a health plan’s costs.
Read moreSummit Re Appoints Greg Demars as President
Summit Reinsurance Services, Inc. today announced the appointment of Greg Demars as President as of January 1, 2020.
Read moreDisclosure and Insurability
One of the crucial steps in finalizing reinsurance coverage is disclosure. When preparing a quote, the reinsurer performs a careful analysis of reinsurance claim costs and trends, including an analysis of the current year's activity. A critical assumption is the degree to which this data can be considered complete. Disclosure helps the reinsurer solidify the accuracy of this assumption.
Read moreNew Specialty Pharmacy Program for Summit Re Clients
Summit Reinsurance Services, Inc. today announced a strategic collaboration with RxResults, a pharmacy risk manager. Through this collaboration, Summit Re clients will have access to proprietary informatics, clinical expertise, and business processes to help formulate actionable insights and implement evidence-based strategic initiatives in order to manage pharmacy and specialty pharmacy spend.
Read moreSummit Re Announces Collaboration with Deerwalk, Inc.
Summit Reinsurance Services, Inc. today announced a strategic collaboration with Deerwalk, Inc., an innovative population health management, data management, and healthcare analytics software company. Through this collaboration, Summit Re clients will have access to the most complete population health management suite in the industry. Efficient and accurate data collection, intake, enrichment, and reporting, will allow participating clients to obtain a full picture of their risk portfolio in order to make more effective management decisions.
Read moreTransplantation and Expanded Criteria Donors: Hepatitis C
This shortage of available organs has led to the increased use of Expanded Criteria Donors in transplant centers for many different organs. This article discusses liver transplant recipients who are hepatitis C negative and receive a liver from an expanded criteria liver donor who is Hepatitis C positive.
Read moreSummit ReSources 2018 Outcomes
Summit ReSources helped clients realize more than $30 million in savings for 2018.
Read moreEligibility – Best Practices for Health Insurers
Healthcare reform will continue to require more responsibility from employers – especially small employers – which will, in turn, require more oversight by insurers. If employer groups are not properly enrolling, verifying eligibility, and reporting members, the health plan could find itself at risk with its reinsurer. The best way to avoid potential conflicts is to make sure your master contract is clear – and then to enforce it.
Read moreSummit Moves Forward with Zurich Strategic Alliance
This special edition of Summit Perspectives provides an in-depth explanation of the new Summit Re partnership with Zurich American Insurance Company for catastrophic medical excess of loss business across all product lines.
Read more